KALM Therapeutics develops a non-steroidal topical treatment for eczema and psoriasis that utilizes targeted anti-inflammatory compounds to reduce skin irritation and inflammation. This approach provides patients with an effective alternative to traditional steroid-based therapies, minimizing side effects while improving skin health.
Funding
$590.4K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Eczema and psoriasis treatments often rely on topical steroids, which can cause adverse side effects like skin thinning, discoloration, and increased susceptibility to infection with prolonged use. Many patients seek non-steroidal alternatives to manage their symptoms and avoid these complications.
Solution
KALM Therapeutics offers a non-steroidal topical treatment designed to alleviate the symptoms of eczema and psoriasis. Their approach utilizes targeted anti-inflammatory compounds to reduce skin irritation and inflammation without the risks associated with traditional steroid-based therapies. The treatment aims to provide effective relief while promoting overall skin health and minimizing potential side effects. By focusing on targeted action, KALM Therapeutics offers a solution that addresses the root causes of inflammation in eczema and psoriasis, leading to improved patient outcomes.
Target Audience
The primary target audience includes individuals with mild to moderate eczema and psoriasis seeking a non-steroidal topical treatment option to manage their symptoms and improve skin health.
Features
- Non-steroidal formulation to avoid steroid-related side effects
- Targeted anti-inflammatory compounds for effective symptom relief
- Topical application for direct treatment of affected areas
- Designed to reduce skin irritation and inflammation associated with eczema and psoriasis